Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Vaccines for Remission Maintenance in Multiple Myeloma
NCT06435910Phase 1Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in multiple myeloma (MM) and plasmacytoma, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of DC injection at 1 month. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
multiple myeloma (MM)plasmacytoma
Beyond the preview
Go deeper on NCT06435910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435910.